422 results on '"Hood, Brian L."'
Search Results
2. Author Correction: Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities
3. Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities
4. Mapping three-dimensional intratumor proteomic heterogeneity in uterine serous carcinoma by multiregion microsampling
5. Brain proteomic atlas of alcohol use disorder in adult males
6. ProteoMixture: A cell type deconvolution tool for bulk tissue proteomic data
7. Peptide ancestry informative markers in uterine neoplasms from women of European, African, and Asian ancestry
8. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer
9. Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment
10. Multiomic analysis of uterine leiomyomas in self-described Black and White women: molecular insights into health disparities
11. Multi-omic Analysis of Uterine Leiomyomas in Self-Described Black and White Women: Molecular Insights into Health Disparities
12. Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways
13. Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
14. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors
15. Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens
16. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
17. Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
18. ProteoMixture: A Cell Type Deconvolution Tool for Bulk Tissue Proteomics Data
19. Standardization and harmonization of distributed multi-center proteotype analysis supporting precision medicine studies
20. Data Supplement from Extrinsic Apoptosis Is Impeded by Direct Binding of the APL Fusion Protein NPM-RAR to TRADD
21. Data from Progesterone Enhances Calcitriol Antitumor Activity by Upregulating Vitamin D Receptor Expression and Promoting Apoptosis in Endometrial Cancer Cells
22. Supplementary Table Part 1 from Progesterone Enhances Calcitriol Antitumor Activity by Upregulating Vitamin D Receptor Expression and Promoting Apoptosis in Endometrial Cancer Cells
23. Data from Extrinsic Apoptosis Is Impeded by Direct Binding of the APL Fusion Protein NPM-RAR to TRADD
24. Supplementary Table Part 2 from Progesterone Enhances Calcitriol Antitumor Activity by Upregulating Vitamin D Receptor Expression and Promoting Apoptosis in Endometrial Cancer Cells
25. Supplementary Figure 2 from Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
26. Supplementary Table 1 from Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
27. Supplementary Data from Proteomic Analysis of Laser-Captured Paraffin-Embedded Tissues: A Molecular Portrait of Head and Neck Cancer Progression
28. Supplementary Figure 1 from Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
29. Supplementary Methods and Materials from The Role of Protein Binding in Induction of Apoptosis by Phenethyl Isothiocyanate and Sulforaphane in Human Non–Small Lung Cancer Cells
30. Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways
31. Additional file 1 of Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors
32. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line
33. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics
34. Therapeutic and prognostic significance of PARP‐1 in advanced mycosis fungoides and Sezary syndrome
35. Quantitative Mass Spectrometry by Isotope Dilution and Multiple Reaction Monitoring (MRM)
36. Industrialized, Artificial Intelligence-guided Laser Microdissection for Microscaled Proteomic Analysis of the Tumor Microenvironment
37. Proteomic Alterations Associated with Residual Disease in Neoadjuvant Chemotherapy Treated Ovarian Cancer Tissues
38. Distinct profiles of oxidative stress–related and matrix proteins in adult bone and soft tissue osteosarcoma and desmoid tumors: A proteomics study
39. Race‐specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients
40. Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer
41. Additional file 1 of Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
42. Restraint stress and stress hormones significantly impact T lymphocyte migration and function through specific alterations of the actin cytoskeleton
43. Serum proteomics signature of Cystic Fibrosis patients: A complementary 2-DE and LC–MS/MS approach
44. Proteomic analysis of stage I endometrial cancer tissue: Identification of proteins associated with oxidative processes and inflammation
45. Stress hormones mediate drug resistance to paclitaxel in human breast cancer cells through a CDK-1-dependent pathway
46. Development of High-Throughput Mass Spectrometry–Based Approaches for Cancer Biomarker Discovery and Implementation
47. Evaluation of a 4-protein serum biomarker panel—biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)—for the detection of esophageal adenocarcinoma
48. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients
49. CLT1 targets angiogenic endothelium through CLIC1 and fibronectin
50. Application of a Global Proteomic Approach to Archival Precursor Lesions: Deleted in Malignant Brain Tumors 1 and Tissue Transglutaminase 2 Are Upregulated in Pancreatic Cancer Precursors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.